| 000 | 01741 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518100941.0 | ||
| 264 | 0 | _c20200529 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a2352-3964 | ||
| 024 | 7 |
_a10.1016/j.ebiom.2020.102768 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _ade Alwis, Ruklanthi | |
| 245 | 0 | 0 |
_aImpact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. _h[electronic resource] |
| 260 |
_bEBioMedicine _cMay 2020 |
||
| 300 |
_a102768 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Viral _xadverse effects |
| 650 | 0 | 4 | _aCOVID-19 |
| 650 | 0 | 4 | _aCOVID-19 Vaccines |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aConvalescence |
| 650 | 0 | 4 |
_aCoronavirus Infections _xepidemiology |
| 650 | 0 | 4 |
_aDendritic Cells _xvirology |
| 650 | 0 | 4 | _aGlobal Health |
| 650 | 0 | 4 |
_aHost Microbial Interactions _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization, Passive |
| 650 | 0 | 4 |
_aMacrophages _xvirology |
| 650 | 0 | 4 | _aModels, Animal |
| 650 | 0 | 4 |
_aMonocytes _xvirology |
| 650 | 0 | 4 |
_aPandemics _xprevention & control |
| 650 | 0 | 4 | _aPlasma |
| 650 | 0 | 4 | _aPlasmapheresis |
| 650 | 0 | 4 |
_aPneumonia, Viral _xepidemiology |
| 650 | 0 | 4 |
_aReceptors, Fc _ximmunology |
| 650 | 0 | 4 | _aTranslational Research, Biomedical |
| 650 | 0 | 4 |
_aViral Vaccines _ximmunology |
| 650 | 0 | 4 | _aVirus Internalization |
| 650 | 0 | 4 | _aCOVID-19 Serotherapy |
| 700 | 1 | _aChen, Shiwei | |
| 700 | 1 | _aGan, Esther S | |
| 700 | 1 | _aOoi, Eng Eong | |
| 773 | 0 |
_tEBioMedicine _gvol. 55 _gp. 102768 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ebiom.2020.102768 _zAvailable from publisher's website |
| 999 |
_c30910131 _d30910131 |
||